|
1
|
Keir ME, Liang SC, Guleria I, Latchman YE,
Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe
AH: Tissue expression of PD-L1 mediates peripheral T cell
tolerance. J Exp Med. 203:883–895. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan
X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, et al:
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in
clinical trials: A systematic review and meta-analysis. JAMA Oncol.
5:1008–1019. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wright JJ, Salem JE, Johnson DB,
Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J and
Powers AC: Increased reporting of immune checkpoint
inhibitor-associated diabetes. Diabetes Care. 41:e150–e151.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Liu J, Shi Y, Liu X, Zhang D, Zhang H,
Chen M, Xu Y, Zhao J, Zhong W and Wang M: Clinical characteristics
and outcomes of immune checkpoint inhibitor-induced diabetes
mellitus. Transl Oncol. 24(101473)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cho YK and Jung CH: Immune-checkpoint
inhibitors-induced type 1 diabetes mellitus: From Its molecular
mechanisms to clinical practice. Diabetes Metab J. 47:757–766.
2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ikeda M, Tamada T, Takebayashi R, Okuno G,
Yagura I, Nakamori S, Matsumura T, Yoshioka T, Kaneko S and Kanda
N: Development of fulminant type 1 diabetes mellitus in the course
of treatment with atezolizumab for hepatocellular carcinoma. Intern
Med. 62:1775–1779. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xie DY, Ren ZG, Zhou J, Fan J and Gao Q:
2019 Chinese clinical guidelines for the management of
hepatocellular carcinoma: Updates and insights. Hepatobiliary Surg
Nutr. 9:452–463. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee JS, Choi HJ, Kim BK, Park JY, Kim DY,
Ahn SH, Han KH, Baek SE, Chung YE, Park MS, et al: The modified
response evaluation criteria in solid tumors (RECIST) yield a more
accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma
treated with transarterial radioembolization. Gut Liver.
14:765–774. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Pascual J, Attard G, Bidard FC, Curigliano
G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD,
Montagut C, et al: ESMO recommendations on the use of circulating
tumour DNA assays for patients with cancer: a report from the ESMO
precision medicine working group. Ann Oncol. 33:750–768.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Peng Y, Qi X and Guo X: Child-Pugh versus
MELD score for the assessment of prognosis in liver cirrhosis: A
systematic review and meta-analysis of observational studies.
Medicine (Baltimore). 95(e2877)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Le Roy B, Grégoire E, Cossé C, Serji B,
Golse N, Adam R, Cherqui D, Mabrut JY, Le Treut YP and Vibert E:
Indocyanine green retention rates at 15 min predicted hepatic
decompensation in a western population. World J Surg. 42:2570–2578.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Park DJ, Sung PS, Lee GW, Cho S, Kim SM,
Kang BY, Hur W, Yang H, Lee SK, Lee SH, et al: Preferential
expression of programmed death ligand 1 protein in tumor-associated
macrophages and its potential role in immunotherapy for
hepatocellular carcinoma. Int J Mol Sci. 22(4710)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
He X and Xu C: Immune checkpoint signaling
and cancer immunotherapy. Cell Res. 30:660–669. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Passat T, Touchefeu Y, Gervois N, Jarry A,
Bossard C and Bennouna J: Physiopathological mechanisms of
immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and
anti-PD-L1 antibodies in cancer treatment. Bull Cancer.
105:1033–1041. 2018.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
18
|
Brahmer JR, Abu-Sbeih H, Ascierto PA,
Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E,
Johnson DB, et al: Society for immunotherapy of cancer (SITC)
clinical practice guideline on immune checkpoint inhibitor-related
adverse events. J Immunother Cancer. 9(e002435)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Arnaud-Coffin P, Maillet D, Gan HK,
Stelmes JJ, You B, Dalle S and Péron J: A systematic review of
adverse events in randomized trials assessing immune checkpoint
inhibitors. Int J Cancer. 145:639–648. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Naqash AR, Ricciuti B, Owen DH, Florou V,
Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, et al:
Outcomes associated with immune-related adverse events in
metastatic non-small cell lung cancer treated with nivolumab: A
pooled exploratory analysis from a global cohort. Cancer Immunol
Immunother. 69:1177–1187. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Llovet JM, Castet F, Heikenwalder M, Maini
MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS:
Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol.
19:151–172. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang CY, Liu S and Yang M: Regulatory T
cells and their associated factors in hepatocellular carcinoma
development and therapy. World J Gastroenterol. 28:3346–3358.
2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Callahan MK, Postow MA and Wolchok JD:
Targeting T cell co-receptors for cancer therapy. Immunity.
44:1069–1078. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ziogas IA, Evangeliou AP, Giannis D, Hayat
MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L and Tsoulfas
G: The role of immunotherapy in hepatocellular carcinoma: A
systematic review and pooled analysis of 2,402 patients.
Oncologist. 26:e1036–e1049. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nikoo M, Hassan ZF, Mardasi M,
Rostamnezhad E, Roozbahani F, Rahimi S and Mohammadi J:
Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1
monoclonal antibodies: A rapidly evolving strategy. Pathol Res
Pract. 247(154473)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu L, Tsang V, Menzies AM, Sasson SC,
Carlino MS, Brown DA, Clifton-Bligh R and Gunton JE: Risk factors
and characteristics of checkpoint inhibitor-associated autoimmune
diabetes mellitus (CIADM): A systematic review and delineation from
type 1 diabetes. Diabetes Care. 46:1292–1299. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fujisawa R, Haseda F, Tsutsumi C, Hiromine
Y, Noso S, Kawabata Y, Mitsui S, Terasaki J, Ikegami H, Imagawa A
and Hanafusa T: Low programmed cell death-1 (PD-1) expression in
peripheral CD4(+) T cells in Japanese patients with autoimmune type
1 diabetes. Clin Exp Immunol. 180:452–457. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang J, Yoshida T, Nakaki F, Hiai H,
Okazaki T and Honjo T: Establishment of NOD-Pdcd1-/- mice as an
efficient animal model of type I diabetes. Proc Natl Acad Sci USA.
102:11823–11828. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Perdigoto AL, Deng S, Du KC, Kuchroo M,
Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP,
Kirkiles-Smith N, et al: Immune cells and their inflammatory
mediators modify β cells and cause checkpoint inhibitor-induced
diabetes. JCI Insight. 7(e156330)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Osum KC, Burrack AL, Martinov T, Sahli NL,
Mitchell JS, Tucker CG, Pauken KE, Papas K, Appakalai B, Spanier JA
and Fife BT: Interferon-gamma drives programmed death-ligand 1
expression on islet β cells to limit T cell function during
autoimmune diabetes. Sci Rep. 8(8295)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen X, Affinati AH, Lee Y, Turcu AF,
Henry NL, Schiopu E, Qin A, Othus M, Clauw D, Ramnath N and Zhao L:
Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes
Care. 45:1170–1176. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Stamatouli AM, Quandt Z, Perdigoto AL,
Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A,
Rushakoff R, et al: Collateral damage: Insulin-dependent diabetes
induced with checkpoint inhibitors. Diabetes. 67:1471–1480.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang Z, Sharma R, Hamad L, Riebandt G and
Attwood K: Incidence of diabetes mellitus in patients treated with
immune checkpoint inhibitors (ICI) therapy-A comprehensive cancer
center experience. Diabetes Res Clin Pract.
202(110776)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lou S, Cao Z, Chi W, Wang X, Feng M, Lin
L, Ding Y, Liu K, Qu L, Zhao G, et al: The safety concerns
regarding immune checkpoint inhibitors in liver cancer patients
rising mainly from CHB. Front Pharmacol. 14(1164309)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Rodríguez de Vera-Gómez P, Piñar-Gutiérrez
A, Guerrero-Vázquez R, Bellido V, Morales-Portillo C,
Sancho-Márquez MP, Espejo-García P, Gros-Herguido N, López-Gallardo
G, Martínez-Brocca MA and Soto-Moreno A: Flash glucose monitoring
and diabetes mellitus induced by immune checkpoint inhibitors: An
approach to clinical practice. J Diabetes Res.
2022(4508633)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Immune-endocrinology Group, Chinese
society of Endocrinology, Chinese Medical Association. Chinese
expert consensus on immune checkpoint inhibitors-induced endocrine
immune-related adverse events (2020). Chin J Endocrinol Metab.
37:1–16. 2021.(In Chinese).
|
|
40
|
Lo Preiato V, Salvagni S, Ricci C,
Ardizzoni A, Pagotto U and Pelusi C: Diabetes mellitus induced by
immune checkpoint inhibitors: Type 1 diabetes variant or new
clinical entity? Review of the literature. Rev Endocr Metab Disord.
22:337–349. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tittel SR, Laubner K, Schmid SM, Kress S,
Merger S, Karges W, Wosch FJ, Altmeier M, Pavel M and Holl RW: DPV
Initiative. Immune-checkpoint inhibitor-associated diabetes
compared to other diabetes types-A prospective, matched control
study. J Diabetes. 13:1007–1014. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lin C, Li X, Qiu Y, Chen Z and Liu J: PD-1
inhibitor-associated type 1 diabetes: A case report and systematic
review. Front Public Health. 10(885001)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
American Diabetes Association. 2.
Classification and diagnosis of diabetes: Standards of medical care
in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31.
2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
de Filette JMK, Pen JJ, Decoster L,
Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO,
Aspeslagh S, Neyns B, et al: Immune checkpoint inhibitors and type
1 diabetes mellitus: A case report and systematic review. Eur J
Endocrinol. 181:363–374. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Deligiorgi MV and Trafalis DT: A concerted
vision to advance the knowledge of diabetes mellitus related to
immune checkpoint inhibitors. Int J Mol Sci.
24(7630)2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Clotman K, Janssens K, Specenier P, Weets
I and De Block CEM: Programmed cell death-1 inhibitor-induced type
1 diabetes mellitus. J Clin Endocrinol Metab. 103:3144–3154.
2018.PubMed/NCBI View Article : Google Scholar
|
